

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 24 avril 2023 15:34

Laboratory Information

Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	Glanders
Address of laboratory:	Naumburger Str. 96a
Tel.:	036418040
E-mail address:	heinrich.neubauer@fli.de
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Prof. Heinrich Neubauer
Name (including Title and Position) of WOA Reference Expert:	Prof. Heinrich Neubauer
Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CFT	Yes	0	7
Immunoblot	Yes	0	3
ELISA	Yes	0	4

Direct diagnostic tests		Nationally	Internationally

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOA?H MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
positive control serum	CFT	produced		5x100ml	1	Europe
LPS-containing membranes	Immunoblot	produced		15 (for 1500 tests)	1	America

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA?H Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

Yes

NAME OF THE NEW TEST OR DIAGNOSTIC METHOD DEVELOPED	DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)
IdVet Glanders Double-Antigen Multispecies ELISA	Elschner MC, Melzer F, Singha H, Muhammad S, Gardner I, Neubauer H: Validation of a Commercial Glanders ELISA as an Alternative to the CFT in International Trade of Equidae. Frontiers in Veterinary Science 2021, 8(62).

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

Yes

				NO. SAMPLES RECEIVED
--	--	--	--	----------------------

NAME OF WOAHP MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	FOR PROVISION OF CONFIRMATORY DIAGNOSES
CANADA	2022-02-01	CFT, Immunoblot, ELISA		1
SWITZERLAND	2022-02-01	CFT		1
CANADA	2022-06-01	CFT, Immunoblot		1
BRAZIL	2022-07-01	CFT		1
BELGIUM BELIZE	2022-12-01	CFT, Immunoblot		1

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHP Member?

Yes

NAME OF THE WOAHP MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
UKRAINE	Proficiency test CFT	Provision of PT serum samples, analysis of results, provision of certificate
EGYPT	Glanders laboratory twinning training, Proficiency test CFT	Training at FLI CFT, PCR; Provision of PT serum samples

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

Brangsch, H.; Saqib, M.; Sial, A.u.R.; Melzer, F.; Linde, J.; Elschner, M.C. Sequencing-Based Genotyping of Pakistani *Burkholderia mallei* Strains: A Useful Way for Investigating Glanders Outbreaks. *Pathogens* 2022, 11, 614. <https://doi.org/10.3390/pathogens11060614>

b) International conferences:

c) National conferences:

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHA Members?

Yes

a) Technical visit :

b) Seminars :

c) Hands-on training courses: 1

d) Internships (> 1 month)

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
c	Egypt	1

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025		Akkreditierungsurkunde_2022.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Microbiological, serological and molecular diagnosis and NGS characterisation of glanders	DAKKS

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

following the German law of Biostoff-Verordnung, e.g. Access control to all labs by administrative regulations, Existence of a Biorisk Committee, regularly audits by external responsible authorities

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOA REF. LABS/ ORGANISING WOA REF. LAB.
-------------------------------------	--	------------------	---

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOA REF. LABS/ ORGANISING WOA REF. LAB.
CFT	participant		ANSES France

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

TITLE OF THE PROJECT OR CONTRACT	SCOPE	NAME(S) OF RELEVANT WOA REFERENCE LABORATORIES
ANSES, France	Development of Glanders standard sera	CVRL, ANSES, NRCE, FLI

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Region(s) of participating WOA Member Countries
CFT Glanders	participant	20	Europe MiddleEast
Cultural identification, PCR and NGS analysis of <i>B. mallei</i> / <i>B. pseudomallei</i>	participant	10	Europe

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOH?

No

29. Additional comments regarding your report: